Difficult to treat psoriatic arthritis - how should we manage?

Clin Rheumatol. 2023 Sep;42(9):2251-2265. doi: 10.1007/s10067-023-06605-9. Epub 2023 Apr 25.

Abstract

Psoriatic arthritis (PsA) is a chronic, multi-domain immune-mediated inflammatory arthritis with a high disease burden. PsA patients have significant co-morbidities like obesity, depression, fibromyalgia which can impact disease activity assessment. The management of PsA has undergone a paradigm shift over the last decade due to the availability of multiple biologic and targeted synthetic disease modifying anti-rheumatic drugs. Despite the availability of multiple therapeutic agents, it is not uncommon to find patients not responding adequately and continuing to have active disease and/or high disease burden. In our review, we propose what is "difficult to treat PsA", discuss differential diagnosis, commonly overlooked factors, co-morbidities that affect treatment responses, and suggest a stepwise algorithm to manage these patients.

Keywords: Biologic therapy; Comorbidities; Difficult-to-treat; Disease activity; Psoriatic arthritis (PsA).

Publication types

  • Review

MeSH terms

  • Antirheumatic Agents* / therapeutic use
  • Arthritis, Psoriatic* / diagnosis
  • Arthritis, Psoriatic* / drug therapy
  • Arthritis, Psoriatic* / epidemiology
  • Comorbidity
  • Cost of Illness
  • Fibromyalgia* / drug therapy
  • Humans

Substances

  • Antirheumatic Agents